Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,583.28
(
-0.63%
)
US TECH 100
23,692.80
(
-0.43%
)
Dow Jones
45,858.50
(
-0.79%
)
Brent Oil
108.90
(
2.17%
)
Bitcoin
69,251.94
(
-2.79%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 169754

Monday, 11/11/2013 9:47:33 AM

Monday, November 11, 2013 9:47:33 AM

Post# of 257259
PTLA—Inasmuch as PRT4445 was able to inhibit Eliquis (#msg-87707322), it would have been very surprising if it didn’t also inhibit Xarelto, since Eliquis and Xarelto work exactly the same way.

PRT4445 still has a long way to go, and (as noted in #msg-91053501) I’m skeptical that the FDA will approve it based on only phase-2 PoC studies and a single PD study, as PTLA contends.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now